Spexis AG (PPHOF)
| Previous close | 2.5000 |
| Open | 2.5000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 2.5000 - 2.5000 |
| 52-week range | 2.5000 - 2.5000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 28.891M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.9800 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Spexis provides business update
Ad hoc announcement pursuant to Art. 53 LRCash position to finance operations extended into January 2023Resources focused on advancing lead program, Phase 3 ColiFin®Assessment of balixafortide development options continues; balixafortide PK/safety clinical trial in renally impaired subjects completed; results expected to be reported this fallProgress in earlier-stage pipeline derived from macrocycle platformVariety of partnering and funding options being vigorously exploredCompany renews equity-
- EQS Group
Spexis announces business update call to be held on July 28th
Spexis AG / Key word(s): ConferenceSpexis announces business update call to be held on July 28th 25.07.2022 / 19:25 Allschwil, Switzerland, July 20, 2022Spexis announces business update call to be held on July 28th Conference call scheduled for Thursday, July 28, 2022, at 8 AM EDT / 2 PM CETSpexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a business update call on Thursday, July 28, 2022, at 8 AM ED
- EQS Group
Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model
Spexis AG / Key word(s): Research UpdateSpexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model 07.07.2022 / 07:30 Allschwil, Switzerland, July 7, 2022Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical modelSPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhi
